Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of BioNTech's Gotistobart?
Gotistobart is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Adenoid Cystic Carcinoma (ACC). According...
Gotistobart by OncoC4 for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Gotistobart is under clinical development by OncoC4 and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Gotistobart by OncoC4 for Solid Tumor: Likelihood of Approval
Gotistobart is under clinical development by OncoC4 and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Gotistobart by OncoC4 for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
Gotistobart is under clinical development by OncoC4 and currently in Phase II for Adenoid Cystic Carcinoma (ACC). According to GlobalData,...